Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR)
Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR) Presentation of Phase 1/2 LIBRETTO-001 trial data will highlight safety and efficacy data of Retevmo® (selpercatinib) in the treatment of RET fusion-positive cancers outside of lung and thyroid cancer Preclinical characterization data will be presented for oral SERD, BCL2 inhibitor, next-generation KRAS-G12C, and RET inhibitors News provided by Share this article Share this article INDIANAPOLIS, March 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from progr...